Conversation with The Cancer LetterFree Klausner: CRUK Grand Challenge—more than just another grant July 21, 2017Vol.43 No.29By Paul Goldberg
Free Cancer Research UK awarding £20 million Grand Challenge grants to cancer researchers worldwide July 21, 2017Vol.43 No.29By Paul Goldberg
ODAC unanimously recommends approval for CAR T-cell therapy for relapsed and refractory B-cell ALL in kids and young adults July 14, 2017Vol.43 No.28By Claire Dietz and Paul Goldberg
Removed from U.S. market in 2011, Pfizer’s Mylotarg slated to return following results of a French study that tested a new regimen July 14, 2017Vol.43 No.28By Paul Goldberg
FY18 health budget battle begins: House appropriators slate $1.1 billion increase for NIH while defunding ACA, Title X July 14, 2017Vol.43 No.28By Matthew Bin Han Ong
Free NCI-MATCH keeps enrolling—Targeted mutations are proving to be less common than estimated July 07, 2017Vol.43 No.27By Paul Goldberg
Conversation with The Cancer LetterFree Keith Flaherty: We will certainly stop if we enroll all subprotocols July 07, 2017Vol.43 No.27By Paul Goldberg
Conversation with The Cancer LetterFree Barbara Conley: Learning from first broad foray into precision medicine July 07, 2017Vol.43 No.27By Paul Goldberg
Free James Doroshow: NCI-MATCH tests ability to integrate next generation sequencing July 07, 2017Vol.43 No.27
Drugs & Targets FDA approves Vectibix for use in wild-type ras metastatic colorectal cancer July 06, 2017Vol.40 No.06
